Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces Settlement of Ethyol(R) ANDA Patent Litigation
Date:8/2/2009

DETROIT, Aug. 3 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announces today that it has executed a settlement agreement with MedImmune, stipulating the dismissal of the lawsuits filed in the United States District Court for the District of Maryland regarding the submission of an Abbreviated New Drug Application (ANDA) for a generic version of Ethyol(R).

Under the settlement agreement, MedImmune grants Caraco a license to certain patents, permitting Caraco to continue marketing a generic version of Ethyol(R) in the United States. The settlement resolves the entirety of the litigations between the parties.

The terms of the settlement are confidential.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as Jitendra N. Doshi Assumes Position of CEO
2. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010
3. Caraco Pharmaceutical Laboratories, Ltd. Announces Filing of Purported Class Action Lawsuits
4. Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to LEXAPRO(R) Patent Litigation
5. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
6. Caraco Pharmaceutical Laboratories, Ltd. Announces an Indefinite Reduction in its Workforce
7. Caraco Pharmaceutical Laboratories, Ltd. Updates on Financial Position
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Action
9. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Fiscal Year 2009, Updates on FDA Inspection
10. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Roxicodone(R) Tablets
11. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Topamax(R) Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... 03, 2016 , ... With the opioid epidemic now at the forefront, attention ... use. Alcohol and its misuse causes long-term consequences for all aspects of society, ... in those 65 years and older. In addition, there is the long term ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... DNA or RNA from a random library of sequences depending on their attraction ... or diagnostic agents. SELEX selection is commonly performed using filters, panning, or affinity ...
(Date:5/3/2016)... ... 2016 , ... Sandbox, one of the nation’s leading independent ... newly created position of executive vice president, chief creative officer.     , In his ... and LA offices. He reports to Nancy Finigan, president of those offices. , ...
(Date:5/3/2016)... ... , ... Elizabeth Murray has always loved walking one to two miles a ... shoulder and one on her arm. But she got to the point where she ... prolapse. , The valves of the heart wouldn’t close properly resulting in mitral regurgitation, ...
(Date:5/3/2016)... ... 03, 2016 , ... Excessive panting in the car or cowering when new ... often think anxiety only manifests itself as trembling or ‘tail between the legs,’ but ... that be done about it,” says Dr. Jim Lowe, technical services veterinarian for Tomlyn ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... acquired a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and ... ... ... ... ...
(Date:5/3/2016)...   BIOTRONIK will be exhibiting and initiating ... implant at the Heart Rhythm Society,s 37 th ... Francisco . "Physicians and hospitals ... patient care and satisfaction possible. Part of that process ... tomorrow," said Marlou Janssen , President, BIOTRONIK, Inc. ...
(Date:5/3/2016)... , May 3, 2016 ... INTP), a clinical-stage biopharmaceutical company, today announced the appointment ... and Regulatory Affairs. "Ms. Strauss-Levy has 15 ... and has established an outstanding track record, having supported ... and regulatory approval processes in the United ...
Breaking Medicine Technology: